OBJECTIVE: Ki-67 is a biomarker that reflects the cell proliferation state. Despite a clear understanding of the protein's structure and properties, its functional role remains elusive. We conducted the present study to assess the prognostic value of Ki-67 in breast cancer (BC). METHODS: We enrolled 164 individuals in this study: 30 patients with benign tumors and 134 with invasive BC. Immunohistochemistry (IHC) was used to detect Ki-67 expression The prognostic value of Ki-67 for 5-year recurrence-free survival (RFS) could be analyzed in 134 BC patients. RESULTS: Ki-67 expression showed significant differences with the tumor grade, lymph node (LN) status, HER2 status and hormone receptor (HR) status (all P<0.05). When Ki- 67 11% was used as cutoff to divide the 134 cases into two groups, with high and low expression, the patients in former had a significantly higher 5-year recurrence rate (37.1% vs 8.1%, P=0.001) and a worse RFS (log-rank test, P=0.0017) than those in low Ki-67 expression group. Ki-67 was an independent prognostic predictor of 5-year RFS in both univariate and multivariate analyses. CONCLUSIONS: Ki-67 can be used as a negative predictor of 5-year RFS of patients with invasive BC.
OBJECTIVE: Ki-67 is a biomarker that reflects the cell proliferation state. Despite a clear understanding of the protein's structure and properties, its functional role remains elusive. We conducted the present study to assess the prognostic value of Ki-67 in breast cancer (BC). METHODS: We enrolled 164 individuals in this study: 30 patients with benign tumors and 134 with invasive BC. Immunohistochemistry (IHC) was used to detect Ki-67 expression The prognostic value of Ki-67 for 5-year recurrence-free survival (RFS) could be analyzed in 134 BC patients. RESULTS: Ki-67 expression showed significant differences with the tumor grade, lymph node (LN) status, HER2 status and hormone receptor (HR) status (all P<0.05). When Ki- 67 11% was used as cutoff to divide the 134 cases into two groups, with high and low expression, the patients in former had a significantly higher 5-year recurrence rate (37.1% vs 8.1%, P=0.001) and a worse RFS (log-rank test, P=0.0017) than those in low Ki-67 expression group. Ki-67 was an independent prognostic predictor of 5-year RFS in both univariate and multivariate analyses. CONCLUSIONS: Ki-67 can be used as a negative predictor of 5-year RFS of patients with invasive BC.
Authors: Aziza Nassar; Tanya L Hoskin; Melody L Stallings-Mann; Amy C Degnim; Derek C Radisky; Marlene H Frost; Robert A Vierkant; Lynn C Hartmann; Daniel W Visscher Journal: Breast Cancer Res Treat Date: 2015-04-12 Impact factor: 4.872
Authors: Jing Ping Yuan; Lin Wei Wang; Ai Ping Qu; Jia Mei Chen; Qing Ming Xiang; Chuang Chen; Sheng-Rong Sun; Dai-Wen Pang; Juan Liu; Yan Li Journal: PLoS One Date: 2015-04-09 Impact factor: 3.240
Authors: Mohammad R Mohebian; Hamid R Marateb; Marjan Mansourian; Miguel Angel Mañanas; Fariborz Mokarian Journal: Comput Struct Biotechnol J Date: 2016-12-06 Impact factor: 7.271
Authors: Praveen-Kumar Raj-Kumar; Jianfang Liu; Jeffrey A Hooke; Albert J Kovatich; Leonid Kvecher; Craig D Shriver; Hai Hu Journal: Sci Rep Date: 2019-05-28 Impact factor: 4.379